1. Thailand Stocks

  2. •

    Healthcare

  3. •

    Medical - Care Facilities
Bumrungrad Hospital Public Company Limited

Bumrungrad Hospital Public Company Limited

BUHPF
Bumrungrad Hospital Public Company LimitedUS flagOther OTC
5.45
USD
- -
- -
4.33BMarket Cap
Bumrungrad Hospital Public Company Limited
BUHPF
(Other OTC)

Recent

price

5.45

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
13.45
15.29
17.82
19.69
21.45
24.24
24.59
24.82
25.15
25.35
15.82
15.68
26.07
31.92
32.35
- -
31.72
Revenue per Share
1.73
2.18
3.51
3.46
3.75
4.72
4.98
5.41
5.7
5.14
1.54
1.53
6.21
8.81
9.78
- -
9.45
Basic EPS, GAAP
1.31
1.33
2.75
1.43
3.61
3.36
3.73
4.91
5.27
4.13
1.62
3.26
6.28
6.82
9.25
- -
7.74
Free Cash Flow per Basic Share
0.85
0.95
1.25
1.9
1.9
2.15
2.4
2.55
2.8
2.95
3.25
3.2
3.2
3.7
5.16
- -
5
Dividend per Share
7.18
8.2
10.07
11.56
13.34
15.82
18.37
21.13
24.04
26.47
22.95
20.95
24.09
29.18
33.8
- -
38.09
Book Value per Share
7.94
9.19
11.36
12.91
15.1
17.59
19.69
22.08
24.53
26.65
23.1
21.18
24.28
29.47
34.16
- -
38.31
Tangible Book Value per Share
728
728
728
729
729
729
729
729
729
729
782
795
795
795
795
- -
795
Basic Weighted Avg Shares
9,794
11,136
12,983
14,346
15,630
17,660
17,915
18,087
18,326
18,474
12,362
12,460
20,721
25,376
25,718
25,215
25,215
Sales/Revenue/Turnover
16.41
19.09
19.62
21.47
21.91
24.01
24.87
26.73
27.73
24.48
11.07
12.66
29.01
33.39
35.73
36.07
36.07
Operating Margin (%)
596
648
709
882
1,045
1,045
1,139
1,206
1,180
1,223
1,220
1,180
1,117
1,097
1,077
1,068
1,068
Depreciation Expense
1,258
1,588
2,558
2,521
2,730
3,436
3,626
3,944
4,152
3,748
1,204
1,216
4,938
7,006
7,775
7,512
7,512
Net Income, GAAP
28.73
24.17
23.79
19.88
20.04
19.37
17.68
17.58
17.48
17.06
10.92
14.83
17.73
18.32
17
18.68
18.68
Effective Tax Rate (%)
12.85
14.26
19.7
17.57
17.47
19.46
20.24
21.81
22.66
20.29
9.74
9.76
23.83
27.61
30.23
29.79
29.79
Profit Margin (%)
132
1,198
5,532
5,389
6,177
6,032
6,445
6,903
9,217
9,097
6,383
5,778
8,004
11,501
12,818
14,696
14,696
Working Capital
1,359
4,955
4,960
5,142
5,152
3,664
3,689
2,508
2,512
2,513
74
54
40
74
102
84
84
LT Debt
6,069
6,952
8,510
9,597
11,260
13,100
14,788
16,705
18,744
20,265
18,837
17,618
20,005
24,098
27,801
31,171
31,171
Total Equity
15.11
16.21
15.05
17.18
17.31
19.43
19.76
20.34
19.9
16.86
5.52
6.91
25.96
30.61
28.77
24.6
24.6
Return on Invested Capital (%)
20.05
19.58
23.6
20.41
19.95
22.25
22.21
22.13
21.48
18.04
6.06
6.82
26.8
32.3
30.35
25.73
25.73
Return on Capital (%)
25.47
28.35
38.45
31.99
30.1
32.34
29.11
27.41
25.23
20.36
6.47
7.03
27.59
33.1
31.06
26.29
26.29
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
37
22
23
LT Borrowings
23
23
23
LT Finance Leases
71
66
61
Preferred Equity and Hybrid Capital
1
1
1
Shares Outstanding
795
795
795
Market Capitalization
125,421
125,179
141,687

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
16,986
16,740
18,781
Cash, Cash Equivalents & STI
12,389
12,561
13,948
Accounts Receivable, Net
4,013
3,623
4,269
Inventories
300
301
371
Total Current Liabilities
3,736
3,546
4,085
Payables & Accruals
3,502
3,324
3,841
ST Debt
37
22
23
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.41%
11.01%
12.12%
Free Cash Flow
19.55%
44.99%
-16.25%
Net Income, GAAP
29.86%
71.33%
-3.38%
Sales/Revenue/Turnover
6.04%
17.79%
-1.95%
Total Cash Common Dividend
10.33%
10.4%
-3.08%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
6,069
6,049
6,741
6,516
25,376
2024
6,537
6,303
6,405
6,473
25,718
2025
6,141
6,024
6,513
6,537
25,215

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
1.99
2.2
2.46
- -
8.81
2024
2.5
2.43
2.46
- -
9.78
2025
2.18
2.34
2.56
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
2.35
1.35
- -
3.7
2024
- -
3.15
2.01
- -
5.16
2025
- -
3
2
- -
- -
Similar Companies
Vibhavadi Medical Center Public Company Limited (VIBHA.BK)
Talkspace, Inc. (TALKW)
Novation Companies, Inc. (NOVC)
The Joint Corp. (JYNT)
MCI Onehealth Technologies Inc. (DRDR.TO)
JD Health International Inc. (JDHIF)
Business
Bumrungrad Hospital Public Company Limited operates Southeast Asia's largest private hospital network, providing comprehensive multi-specialty healthcare services including inpatient and outpatient care across 47 specialty centers and clinics; behavioral health, diabetes management, digestive disease treatment, hyperbaric oxygen therapy, joint replacement, rehabilitation, travel medicine, refractive surgery, cardiac care, oncology, orthopedics, neurology, fertility treatments, precision medicine, robotic-assisted surgery with da Vinci and MAKOplasty systems, and advanced diagnostics such as CardioInsight for heart arrhythmias. The company, founded in 1980 and headquartered in Bangkok, Thailand, manages Bumrungrad International Hospital with 580 licensed beds as its primary revenue source contributing over 93% of group revenues; subsidiaries and affiliates include Vitallife Scientific Wellness Center, VitalLife Skin Clinic, Bumrungrad International Dialysis Clinic, Esperance Cancer Clinic, and Bumrungrad International Clinic in Bangkok, Bumrungrad Clinic Yangon in Myanmar, and Ulaanbaatar Songdo Hospital in Mongolia. It serves over 1.1 million patients annually, including more than 643,000 international episodes from over 190 countries with key markets in Qatar, Myanmar, and the United States; operations emphasize medical tourism, clinical research, property rental, and wellness services generating 65% of revenues from overseas patients. In recent developments, the company reports robust Q2 2025 results exceeding expectations driven by Middle East market recovery and plans a major expansion project estimated at over 4.3 billion THB set to open by end-2027 for enhanced international patient capacity; it received Money & Banking Awards 2025 recognition in the healthcare sector for the second consecutive year, a Board of Investment of Thailand certificate of appreciation in May 2025, and announced Q3 2025 operating results alongside an independent director appointment in November 2025.